Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Gossamer Bio to Present at Cantor Global Healthcare Conference

Friday, September 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Gossamer Bio, a clinical-stage biopharmaceutical company, will present at the Cantor Global Healthcare Conference scheduled for September 9-11, 2026. The company focuses on developing seralutinib for pulmonary arterial hypertension and related conditions. This event is expected to provide an opportunity for Gossamer to showcase its advancements and engage with investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Gossamer Bio is actively engaging with the investment community.
  • The presentation may enhance visibility for seralutinib.
  • Participation in a notable healthcare conference indicates growth potential.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026. Cantor Global Healthcare Conference Date / Time: September 9th,

Frequently Asked Questions

What is Gossamer Bio presenting at the conference?

Gossamer Bio will present its developments related to seralutinib.

When is the Cantor Global Healthcare Conference?

The conference will take place from September 9-11, 2026.

What conditions does seralutinib target?

Seralutinib is aimed at treating pulmonary arterial hypertension and PH-ILD.

Where is Gossamer Bio based?

Gossamer Bio is based in San Diego.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Gossamer Bio seralutinib pulmonary arterial hypertension Cantor Global Healthcare Conference biopharmaceutical
Last updated: Sep 4, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →